GNPX News and Press, Genprex Inc. From 01/27/22

What’s going on in the stock market today? You probably know that things have been very volatile if you’ve been watching the trading action over the last month. And no class of stocks enjoys volatility quite like penny stocks . There aren’t many places where you can...

Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that its collaborators published positive preclinical data for the use of Genprex’s ONCOPREX(R) Nanoparticle Delivery S...

Academic Research Lab Uses ONCOPREX Delivery System to Restore FAS Expression in Mouse Metastatic Colon-Cancer Cells Data Supports Expansion of ONCOPREX Delivery System, Currently the Subject of Lung Cancer Clinical Trials, to Additional Therapeutic Genes and Other Types of Ca...

Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced a plan to accelerate the opening of clinical trial sites for the Acclaim-1 clinical trial. The trial combines the company ...

Multiple clinical trial sites to be opened under oncology research network collaboration Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for pa...

Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, will be participating in two January conferences. The company announced that president and CEO Rodney Varner and chief medical officer Mark Ber...

HC Wainwright BIOCONNECT 2022 Virtual Conference - January 10-13 Biotech Showcase 2022 - January 10-13 Precision: Lung Cancer World R&D Virtual Summit - January 25-26 CEO Roadshow - January 26 Genprex, Inc. (“Genprex” or the “Company ...

Fast Track Designation With Immunotherapy. Genprex announced that the FDA has granted Fast Track Designation (FTD) for Reqorsa in combination with Keytruda (pembrolizumab) to treat non-small cell lung cancer (NSCLC). The company reiterated plans start testing the combination in the Phase 2 ACC...

Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that it has expanded its oncology research and development pipeline to include small cell lung cancer (“SCLC”) a...

Pipeline Expansion Enables Company to Target Entire Lung Cancer Market with REQORSA™ Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for...